ArticleOpen heart2020
Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.
Article in Open heart, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.American journal of therapeutics · 2021Pooled it
- Trial
- Trial
- Therapeutic and Formulation Advances of Ivermectin in Veterinary and Human Medicine.Pharmaceutics · 2025Review
- Ivermectin attenuatesFrontiers in cellular and infection microbiology · 2025Article
- Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients.Cureus · 2024Article
- Unveiling the Potential of Silymarin,Life (Basel, Switzerland) · 2024Article
- ACV with/without IVM: a new talk on intestinal CDX2 and muscular CD34 and Cyclin D1 duringHelminthologia · 2024Article
- Article
- What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms.Virology journal · 2023Review
- Ivermectin Attenuates CClInternational journal of molecular sciences · 2022Article
- Review
- Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic.Life (Basel, Switzerland) · 2022Review
- Potential therapeutic effects of Ivermectin in COVID-19.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Article
- Strategies for drug repurposing against coronavirus targets.Current research in pharmacology and drug discovery · 2022Review
- Using a Systems Approach to Explore the Mechanisms of Interaction Between Severe Covid-19 and Its Coronary Heart Disease Complications.Frontiers in cardiovascular medicine · 2022Article
- Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics.Scientific reports · 2021Article
- Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway.Expert opinion on pharmacotherapy · 2021Article
- Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors.Open heart · 2021Article
Corrections and comments
- Commented on by
- Erratum issuedCorrection:2020
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.